DW ASCO 2022 – Metastatic Breast Cancer

Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer

The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone receptor (HR)-positive, human epidermal growth factor...

“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer

Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated significant survival benefit with trastuzumab deruxtecan...

These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases

Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting indicated that the following prognostic factors impact overall survival (OS) in...

Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer

Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor activity in patients with HER2-positive...

ASCO 2022

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews